Equity Overview
Price & Market Data
Price: $0.611
Daily Change: +$0.0196 / 3.21%
Range: $0.568 - $0.62
Market Cap: $15,244,301
Volume: 40,546
Performance Metrics
1 Week: 13.01%
1 Month: 4.41%
3 Months: -23.68%
6 Months: -36.55%
1 Year: -79.31%
YTD: -16.37%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.